These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29923299)

  • 1. Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study.
    Melmer A; Kempf P; Lunger L; Pieber TR; Mader JK; Stettler C; Tilg H; Ebenbichler CF; Laimer M
    Diabetes Obes Metab; 2018 Nov; 20(11):2685-2689. PubMed ID: 29923299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Singh R; Fawaz M; DeFronzo RA; Jayyousi A
    Diabetes Obes Metab; 2019 Mar; 21(3):705-709. PubMed ID: 30259621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
    Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
    Burggraaf B; Pouw NMC; Fernández Arroyo S; van Vark-van der Zee LC; van de Geijn GM; Birnie E; Huisbrink J; van der Zwan EM; de Herder WW; Mulder MT; Rensen PCN; Castro Cabezas M
    Eur J Endocrinol; 2022 Apr; 186(5):597-605. PubMed ID: 35312632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
    van Meijel LA; Tack CJ; de Galan BE
    Diabetes Obes Metab; 2021 Nov; 23(11):2582-2589. PubMed ID: 34338413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
    Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin for the treatment of type 1 diabetes mellitus.
    Pafili K; Maltezos E; Papanas N
    Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND; Ghanim H; Mehta A; Garg M; Khan S; Hejna J; Torre B; Makdissi A; Chaudhuri A; Batra M; Dandona P
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3506-15. PubMed ID: 27490915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.